We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Increased Risk of Death With Advair, Serevent, Foradil, Study Says
Increased Risk of Death With Advair, Serevent, Foradil, Study Says
June 6, 2006
Long-acting bronchodilators — also known as long-acting beta-agonists (LABAs) — should be pulled off the market because patients are four to six times more likely to die from asthma symptoms and were hospitalized twice as often as patients on placebos, according to a study to be published in the June 20 issue of the journal Annals of Internal Medicine.